QT Imaging’s Breast Acoustic CT™ Scanner Used in Study for Early Identification of Response of Breast Cancer Patients to Neoadjuvant Chemotherapy
- None.
- None.
Insights
The delivery of QT Imaging Holdings' Breast Acoustic CT™ Scanner to major research institutions, funded by a National Institutes of Health/National Cancer Institute grant, signifies a notable step in breast cancer diagnostic technology. The focus on developing an inexpensive, portable and safe imaging system addresses a critical gap in the current cancer treatment paradigm. Quantitative imaging, such as that provided by the Breast Acoustic CT™, could revolutionize the way clinicians monitor the efficacy of neoadjuvant chemotherapy (NAC) in real-time.
The potential for this technology to offer early identification of non-responders to NAC is particularly significant. Current methods can take months to determine effectiveness, which can delay alternative treatment plans for non-responders. The ability to adjust treatment strategies quickly could improve patient outcomes and reduce unnecessary exposure to ineffective therapies. Moreover, the emphasis on dense breast tissue and young women with risk factors suggests that this technology could fill a niche where mammography has limitations.
The collaboration between QT Imaging Holdings and leading academic centers could lead to advancements in adaptive precision medicine in breast cancer therapy. The Breast Acoustic CT™ system's potential in providing quantitative ultrasound-based biomarkers for cancer response to therapy is a promising development. In oncology, the precision of radiomic data is crucial for tailoring treatment to individual patient profiles. The ability to derive quantitative markers with improved estimate precision over conventional ultrasound scanners could enable more personalized and effective treatment plans.
Furthermore, the technology's suitability for dense breasts and young women, who are often at a disadvantage with traditional imaging techniques, represents a significant improvement in diagnostic methodologies. By providing high-resolution, 3D, quantitatively accurate breast images without discomfort or safety concerns, the Breast Acoustic CT™ system could enhance the patient experience and potentially improve compliance with screening recommendations.
The economic implications of introducing a cost-effective and efficient diagnostic tool like the Breast Acoustic CT™ scanner are substantial. By potentially reducing the time to identify ineffective cancer treatments, healthcare systems could allocate resources more efficiently and reduce the financial burden associated with prolonged, unproductive chemotherapy cycles. In the long term, if the technology proves to be widely effective and adopted, it could lead to significant cost savings for both patients and healthcare providers.
Additionally, the focus on creating a portable imaging device aligns with the trend towards decentralization of healthcare services. If the Breast Acoustic CT™ system can be operated outside traditional hospital settings, it could increase access to high-quality cancer diagnostics, particularly in underserved or rural areas, further driving down healthcare disparities and potentially improving overall health outcomes.
As part of this grant, Breast Acoustic CT™ (ACT) quantitative images with independent biomarkers known to be sensitive to cancer will be collected, and the response of cancer to therapy, will be derived from quantitative ultrasound based on backscatter analysis. The successful results of this collaboration will yield additional quantitative markers (radiomics) with improved estimate precision not afforded by conventional ultrasound scanners.
This collaboration also addresses the ongoing clinical need in breast cancer therapy for the development of an inexpensive, robust, and accurate technique to identify the response, within weeks, of breast cancer to neoadjuvant chemotherapy. The early identification of non-responders to NAC or any cancer treatment remains a highly significant medical problem and necessary for adaptive precision medicine.
"The QTI Breast Acoustic CT™ System represents the future of tomographic imaging, offering quantitatively accurate, 3D, high resolution breast images, taken with no safety or discomfort for women," said James Wiskin, PhD, Principal Scientist and QTI Fellow. "The ACT system is especially appropriate for dense breasts and young women with risk factors. This partnership serves as a testament to collaborations between leaders in industry and academia."
"Unfortunately, not all therapies work in cancer patients and the ability to determine which are effective and which treatments are ineffective in days instead of months is very important. With the QTI Breast Acoustic CT™ System we plan to implement quantitative ultrasound methods which can be used for exactly that kind of determination to enable personalized care," stated Greg Czarnota, MD, PhD, Clinician Scientist Department of Radiation Oncology at Sunnybrook Health Sciences Centre in
About QT Imaging Holdings, Inc.
QT Imaging Holdings, Inc. is a public (NASDAQ: QTI) medical device company engaged in research, development, and commercialization of innovative body imaging systems using low frequency sound waves. QT Imaging Holdings, Inc. strives to improve global health outcomes. Its strategy is predicated upon the fact that medical imaging is critical to the detection, diagnosis, and treatment of disease and that it should be safe, affordable, accessible, and centered on the patient’s experience. For more information on QT Imaging Holdings, Inc., please visit the company’s website at www.qtimaging.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such statements contain words such as “will,” and “expect,” or the negative thereof or comparable terminology, and include (without limitation) statements regarding the QTI Breast Acoustic CT™ System and its use in the research collaboration and images that may be rendered as part of this research, plans for QT Imaging Holdings, new product development and introduction, and product sales growth and projected revenues. Forward-looking statements involve certain risks and uncertainties, and actual results may differ materially from those discussed in any such statement. These risks include, but are not limited to: the ability of the parties to sell and deploy the QTI Breast Acoustic CT™ System, the ability to extend product offerings into new areas or products, the ability to commercialize technology, unexpected occurrences that deter the full documentation and “bring to market” plan for products, trends and fluctuations in the industry, changes in demand and purchasing volume of customers, unpredictability of suppliers, the ability to attract and retain qualified personnel and the ability to move product sales to production levels. Additional factors that could cause actual results to differ are discussed under the heading “Risk Factors” and in other sections of QT Imaging’s (and its predecessor, GigCapital5, Inc.) filings with the SEC, and in its other current and periodic reports filed or furnished from time to time with the SEC. All forward-looking statements in this press release are made as of the date hereof, based on information available to QT Imaging Holdings as of the date hereof, and QT Imaging Holdings assumes no obligation to update any forward-looking statement.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240314628313/en/
Stas Budagov
Chief Financial Officer
Stas.Budagov@qtimaging.com
Source: QT Imaging Holdings, Inc.
FAQ
What is the ticker symbol for QT Imaging Holdings, Inc.?
What is the purpose of the collaboration between QT Imaging Holdings, Inc. and the Department of Radiation Oncology at Sunnybrook Health Sciences Centre?
What are the key features of the Breast Acoustic CT™ System developed by QT Imaging Holdings, Inc.?
Why is early identification of non-responders to neoadjuvant chemotherapy important in cancer therapy?
Who are the key individuals involved in the development of the Breast Acoustic CT™ System at QT Imaging Holdings, Inc.?
